Literature DB >> 22515115

A permission system for carbapenem use reduced incidence of drug-resistant bacteria and cost of antimicrobials at a general hospital in Japan.

Yoshiaki Ikeda1, Takayoshi Mamiya, Hideki Nishiyama, Shiho Narusawa, Takenao Koseki, Akihiro Mouri, Toshitaka Nabeshima.   

Abstract

Some drug management systems have been established in Japanese hospitals to reduce medical costs and regulate drug usage. Among the many available prescription drugs, antimicrobials should be given special attention because their inappropriate use often leads to sudden outbreaks of resistant bacteria. As drug specialists, pharmacists should monitor the use of all drugs, particularly antimicrobials. Carbapenems are a class of broad-spectrum antimicrobials that are widely used to treat infections worldwide. However, their inappropriate use has led to an increase in the incidence of drug-resistant bacteria and consequently, medical costs, at hospitals. To reduce inappropriate use and drug resistance, we have established a permission system to control the use of carbapenems at the Japanese Red Cross Nagoya Daiichi Hospital. In this study, we retrospectively evaluated the applicability of the new permission system compared to that of the notification system and the non control system for 14 months each. The two management systems were able to maintain total antibiotic use density and control the outbreak of drug-resistant bacteria (P. aeruginosa, E. coli, and K. pneumoniae). The number of carbapenem prescriptions was decreased dramatically when this permission system was enforced. Compared to the non control system, the cost of antimicrobials was reduced by $757,470 for the 14-month study period using the permission system. These results suggest that our system to control the use of antimicrobials can efficiently suppress the incidence of drug-resistant bacteria and medical costs at hospitals.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22515115      PMCID: PMC4831254     

Source DB:  PubMed          Journal:  Nagoya J Med Sci        ISSN: 0027-7622            Impact factor:   1.131


  23 in total

1.  Surveillance of antimicrobial use and antimicrobial resistance in United States hospitals: project ICARE phase 2. Project Intensive Care Antimicrobial Resistance Epidemiology (ICARE) hospitals.

Authors:  S K Fridkin; C D Steward; J R Edwards; E R Pryor; J E McGowan; L K Archibald; R P Gaynes; F C Tenover
Journal:  Clin Infect Dis       Date:  1999-08       Impact factor: 9.079

2.  European surveillance of antimicrobial consumption (ESAC): data collection performance and methodological approach.

Authors:  R H Vander Stichele; M M Elseviers; M Ferech; S Blot; H Goossens
Journal:  Br J Clin Pharmacol       Date:  2004-10       Impact factor: 4.335

3.  Infectious Diseases Society of America and the Society for Healthcare Epidemiology of America guidelines for developing an institutional program to enhance antimicrobial stewardship.

Authors:  Timothy H Dellit; Robert C Owens; John E McGowan; Dale N Gerding; Robert A Weinstein; John P Burke; W Charles Huskins; David L Paterson; Neil O Fishman; Christopher F Carpenter; P J Brennan; Marianne Billeter; Thomas M Hooton
Journal:  Clin Infect Dis       Date:  2006-12-13       Impact factor: 9.079

4.  Benchmark analysis of strategies hospitals use to control antimicrobial expenditures.

Authors:  R P Rifenburg; J A Paladino; S C Hanson; J A Tuttle; J J Schentag
Journal:  Am J Health Syst Pharm       Date:  1996-09-01       Impact factor: 2.637

5.  Risk factors for increasing multidrug resistance among extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella species.

Authors:  Emily P Hyle; Adam D Lipworth; Theoklis E Zaoutis; Irving Nachamkin; Neil O Fishman; Warren B Bilker; Xiangquin Mao; Ebbing Lautenbach
Journal:  Clin Infect Dis       Date:  2005-03-30       Impact factor: 9.079

6.  Effects of requiring prior authorization for selected antimicrobials: expenditures, susceptibilities, and clinical outcomes.

Authors:  A C White; R L Atmar; J Wilson; T R Cate; C E Stager; S B Greenberg
Journal:  Clin Infect Dis       Date:  1997-08       Impact factor: 9.079

7.  Randomized trial of cefepime monotherapy or cefepime in combination with amikacin as empirical therapy for febrile neutropenia.

Authors:  K Tamura; K Imajo; N Akiyama; K Suzuki; A Urabe; K Ohyashiki; M Tanimoto; T Masaoka
Journal:  Clin Infect Dis       Date:  2004-07-15       Impact factor: 9.079

Review 8.  Comparative review of the carbapenems.

Authors:  George G Zhanel; Ryan Wiebe; Leanne Dilay; Kristjan Thomson; Ethan Rubinstein; Daryl J Hoban; Ayman M Noreddin; James A Karlowsky
Journal:  Drugs       Date:  2007       Impact factor: 9.546

Review 9.  The use of carbapenems in the treatment of serious infections.

Authors:  Robert P Baughman
Journal:  J Intensive Care Med       Date:  2009-07-17       Impact factor: 3.510

10.  Recommendations for preventing the spread of vancomycin resistance. Recommendations of the Hospital Infection Control Practices Advisory Committee (HICPAC).

Authors: 
Journal:  MMWR Recomm Rep       Date:  1995-09-22
View more
  2 in total

1.  Enhancing US-Japan cooperation to combat antimicrobial resistance.

Authors:  C Sachi Gerbin
Journal:  Biosecur Bioterror       Date:  2014 Nov-Dec

2.  Does antimicrobial use density at the ward level influence monthly central line-associated bloodstream infection rates?

Authors:  Junichi Yoshida; Yukiko Harada; Tetsuya Kikuchi; Ikuyo Asano; Takako Ueno; Nobuo Matsubara
Journal:  Infect Drug Resist       Date:  2014-12-01       Impact factor: 4.003

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.